Print this page
breast
-
Evaluating, Preparing, and Responding to Care Disruptions and Health Outcomes Among Patients with Breast Cancer Following Severe Storms
Protocol: 002405Applicable Disease Sites: Breast
-
Evaluating, Preparing, and Responding to Care Disruptions and Health Outcomes Among Patients with Breast Cancer Following Severe Storms
Protocol: 002405Applicable Disease Sites: Breast
-
Wholeness in Healing: Evaluating the Effect of Quality of Life (QOL) on Integrative Therapy Interventions Performed During Outpatient Systemic Therapy Treatment for Women with Stage IIII Breast Cancer- A Pilot Study.
Protocol: 002553Applicable Disease Sites: Breast
-
Wholeness in Healing: Evaluating the Effect of Quality of Life (QOL) on Integrative Therapy Interventions Performed During Outpatient Systemic Therapy Treatment for Women with Stage IIII Breast Cancer- A Pilot Study.
Protocol: 002553Applicable Disease Sites: Breast
-
Uncovering the Tumor Microbiome in Breast Cancer: Toward Spatial
Architecture and Risk Stratification
Protocol: 002634Principal Investigator:
- Tengteng Wang
Applicable Disease Sites: Breast -
Uncovering the Tumor Microbiome in Breast Cancer: Toward Spatial
Architecture and Risk Stratification
Protocol: 002634Principal Investigator:
- Tengteng Wang
Applicable Disease Sites: Breast -
Phase II Study to Assess the Efficacy of Combined Tafasitamab and Rituximab in Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder.
Protocol: 012306Principal Investigator:
- Joanna Rhodes
Applicable Disease Sites: Non-Hodgkin Lymphoma -
Phase II Study to Assess the Efficacy of Combined Tafasitamab and Rituximab in Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder.
Protocol: 012306Principal Investigator:
- Joanna Rhodes
Applicable Disease Sites: Non-Hodgkin Lymphoma -
A Phase III, Open-Label, Multicenter, Randomized Study Evaluating Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma.
Protocol: 012403Principal Investigator:
- Matthew Matasar
Applicable Disease Sites: Non-Hodgkin Lymphoma -
A Phase III, Open-Label, Multicenter, Randomized Study Evaluating Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma.
Protocol: 012403Principal Investigator:
- Matthew Matasar
Applicable Disease Sites: Non-Hodgkin Lymphoma -
A Phase 1 First in Human Study of ARV-393 in Adult Participants with Advanced Non-Hodgkins Lymphoma.
Protocol: 012406Principal Investigator:
- Matthew Matasar
Applicable Disease Sites: Non-Hodgkin Lymphoma -
A Phase 1 First in Human Study of ARV-393 in Adult Participants with Advanced Non-Hodgkins Lymphoma.
Protocol: 012406Principal Investigator:
- Matthew Matasar
Applicable Disease Sites: Non-Hodgkin Lymphoma -
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease.
Protocol: 012411Principal Investigator:
- Ogechukwu Egini
Applicable Disease Sites: Hodgkin Lymphoma -
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease.
Protocol: 012411Principal Investigator:
- Ogechukwu Egini
Applicable Disease Sites: Hodgkin Lymphoma -
Phase 2, Single-arm, Open-label, Study of Loncastuximab Tesirine in Combination with Rituximab in Patients with relapsed or refractory Follicular Lymphoma
Protocol: 012501Principal Investigator:
- Joanna Rhodes
Applicable Disease Sites: Non-Hodgkin Lymphoma -
Phase 2, Single-arm, Open-label, Study of Loncastuximab Tesirine in Combination with Rituximab in Patients with relapsed or refractory Follicular Lymphoma
Protocol: 012501Principal Investigator:
- Joanna Rhodes
Applicable Disease Sites: Non-Hodgkin Lymphoma